Successful application of chimeric antigen receptor (CAR)-modified T cells in CD19-positive B cell hematological malignancies has demonstrated the potency of this approach for cancer immunotherapy [6–9], and CAR T cells targeting a variety of different hematologic and solid tumor antigens are under active clinical development [10, 11]. Here, CD19 is linked to cancer.